Sharing success – understanding barriers and enablers to secondary prophylaxis delivery for rheumatic fever and rheumatic heart disease
نویسندگان
چکیده
BACKGROUND Rheumatic fever (RF) and rheumatic heart disease (RHD) cause considerable morbidity and mortality amongst Australian Aboriginal and Torres Strait Islander populations. Secondary antibiotic prophylaxis in the form of 4-weekly benzathine penicillin injections is the mainstay of control programs. Evidence suggests, however, that delivery rates of such prophylaxis are poor. METHODS This qualitative study used semi-structured interviews with patients, parents/care givers and health professionals, to explore the enablers of and barriers to the uptake of secondary prophylaxis. Data from participant interviews (with 11 patients/carers and 11 health practitioners) conducted in four far north Queensland sites were analyzed using the method of constant comparative analysis. RESULTS Deficits in registration and recall systems and pain attributed to injections were identified as barriers to secondary prophylaxis uptake. There were also varying perceptions regarding responsibility for ensuring injection delivery. Enablers of secondary prophylaxis uptake included positive patient-healthcare provider relationships, supporting patient autonomy, education of patients, care givers and healthcare providers, and community-based service delivery. CONCLUSION The study findings provide insights that may facilitate enhancement of secondary prophylaxis delivery systems and thereby improve uptake of secondary prophylaxis for RF/RHD.
منابع مشابه
Enablers and barriers to secondary prophylaxis for rheumatic fever among Māori aged 14–21 in New Zealand: a framework method study
BACKGROUND Acute rheumatic fever (ARF) rates have declined to near zero in nearly all developed countries. However, in New Zealand rates have not declined since the 1980s. Further, ARF diagnoses in New Zealand are inequitably distributed--occurring almost exclusively in Māori (the indigenous population) and Pacific children--with very low rates in the majority New Zealand European population. W...
متن کاملRHEUMATIC FEVER IN lRANIAN CHILDREN: CLINICAL AND PREVENTIVE ASPECTS
A total of70 children aged 6 to 15 years with rheumatic fever and completed in-hospital data were reviewed from 19XX to 1993. In 5X.6% of patients this was the first attack of disease, while in 41.4'10 the episode represented a recurrence. Noncompliance of antimicrobial prophylaxis was noted in all of the subjects with recurrences. 61.4% of cases gave a previous history of sore throat, and ...
متن کاملA case of acute rheumatic fever with new criteria, a disease that needs to be considered
Introduction: Acute rheumatic fever is an autoimmune disease that mainly affects the large joints. Early treatment of a throat infection following group A streptococcus prevents of acute rheumatic fever. Given the low prevalence of the disease, especially in a situation where there is excessive use of antibiotics in Iran, this study intends to report a patient with Acute rheumatic fever with mi...
متن کاملIs primary prevention of rheumatic fever the missing link in the control of rheumatic heart disease in Africa?
Rheumatic fever and rheumatic heart disease continue to be major public health problems in the developing world, particularly in the countries of sub-Saharan Africa. Because of its cost effectiveness, secondary prophylaxis is advocated as the principal means of disease prevention and control. However, in developing countries, valvular damage, due to earlier, unrecognized episodes of rheumatic f...
متن کاملFailure of secondary prophylaxis with erythromycin in rheumatic heart disease.
BACKGROUND Erythromycin is recommended for secondary prophylaxis in children with rheumatic heart disease, who are allergic to penicillin. CASE CHARACTERISTICS A 9-year-old girl, with rheumatic heart disease, on secondary prophylaxis with erythromycin 250 mg BD, presented with acute rheumatic fever. OUTCOME Responded to steroids and started on a higher dose (250 mg TDS) of erythromycin for ...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
عنوان ژورنال:
دوره 16 شماره
صفحات -
تاریخ انتشار 2016